Merck Beats and Re-Rates to a 52-Week High, But a No-Growth 2026 Guide and the Keytruda Cliff Cap the Upside

Results vs. Consensus

Year-over-Year Comparison (Q4'25 vs. Q4'24)

Sequential Comparison (Q4'25 vs. Q3'25)

The sequential step-down is seasonal and mix-driven rather than a sign of deterioration: Q3 carries the back-to-school Gardasil and peak Keytruda seasonality, and Q4 absorbed roughly $200M of Keytruda US purchase-timing that pushed into the prior period, a soft Gardasil quarter with no China shipments, and heavier other-expense.

Quality of Beat/Miss

• Revenue: High quality. The $210M beat was organic and demand-led, spread across Keytruda (earlier-stage and women's cancers), Winrevair (+133% YoY), Capvaxive, Ohtuvayre, and Animal Health. FX added only ~1 point. The ~$200M of Keytruda US purchase-timing that slipped out of the quarter means underlying demand was, if anything, a touch better than the printed number.
• Margins: Lower quality. Non-GAAP gross margin of 79.7% fell 110 bps on higher inventory reserves; operating margin of 20.9% is down 660 bps YoY as Merck front-loads investment behind new launches and the expanded pipeline. Some of this is deliberate and strategic, but it is real margin give-back, and 2026 guidance assumes gross margin recovers to ~82%.
• EPS: Clean at the operating line, flattered slightly below it. The $2.04 includes a $0.05 charge and benefited from a low 15.4% quarterly tax rate. The 18.6% YoY growth in non-GAAP EPS overstates the underlying trajectory given the tax help and the coming step-up in the 2026 tax rate to 23.5–24.5%.

Segment Performance

Oncology (Keytruda and beyond)

Oncology remains the engine. The Keytruda family grew 5% ex-FX to $8.4B, with growth driven by robust uptake in earlier-stage cancers, strong metastatic demand, and utilization in tumors that primarily affect women (breast, cervical, endometrial), plus the Padcev combination in urothelial cancer. US growth was held back by roughly $200M of purchase timing, so the underlying trajectory is healthier than the headline. Beyond Keytruda, Welireg (the first-in-class oral HIF-2α inhibitor) grew 37% to $220M, and the perioperative bladder-cancer approvals (Keytruda plus Padcev) and the positive KEYNOTE-B15 readout extend the franchise into new settings.

"Sales of the Keytruda family of products... increased 5% to $8.4 billion, with global growth driven by robust uptake in earlier-stage cancers and strong demand from metastatic indications." — Caroline Litchfield, CFO

Assessment: The core franchise is executing, and the earlier-stage and women's-cancer mix improves the durability profile heading into the LOE. But every dollar of Keytruda strength today also raises the stakes of the 2028 cliff. The number that matters most is not the $8.4B; it is the pace of the Qlex conversion that has to defend it.

Cardiometabolic & Respiratory (the growth story)

Winrevair (PAH)

Winrevair is the clearest new-franchise win, with global sales of $467M up 133% YoY. More than 1,500 new US patients started therapy in the quarter and over 27,000 total prescriptions were dispensed; cumulatively the drug has surpassed 110,000 prescriptions and 9,100 patients on therapy, with compliance high and discontinuation rates in line with or slightly better than other PAH products. The European Commission's expanded WHO functional class II–IV label (on the ZENITH study) opens the addressable population further.

"Winrevair is reshaping the standard of care in PAH... it is a differentiated pathway and a molecule. All the other drugs... are classic vasodilators. This is a drug that gets to the underlying biology through the genetics." — Dr. Dean Li, President, Merck Research Laboratories

Ohtuvayre (COPD, from Verona)

Ohtuvayre added $178M following the October 7 Verona close, with strong new-patient starts and a widening prescriber base. Management flagged the usual first-quarter seasonality as Medicare deductibles reset.

Assessment: This is the part of the model that supports the "sustainable growth post-LOE" thesis. Winrevair is on a genuine trajectory toward blockbuster status and Ohtuvayre gives Merck a second respiratory launch to scale. These franchises are real, but at a combined run-rate well under $3B annually they are not yet large enough to offset a $31.7B Keytruda; they need the pipeline behind them to convert.

Vaccines (the drag)

Vaccines are the pressure point. Gardasil fell 35% to $1.0B on weak China and Japan demand, with no China shipments recognized in the quarter; other international markets grew 8% on purchase timing and the US grew 7% on price. Capvaxive ($279M) continues a healthy pneumococcal launch, but Enflonsia (RSV) managed only $21M, constrained by lower-than-expected infant immunization rates and high channel inventory of RSV monoclonal antibodies.

"Gardasil sales were $1 billion, a decrease of 35% driven by lower demand in China and Japan." — Caroline Litchfield, CFO

Assessment: Gardasil has moved from growth driver to secular headwind, and 2026 brings a fresh incremental risk from the CDC's move to a single-dose pediatric HPV schedule. Capvaxive is a bright spot; Enflonsia is off to a slow start. Net, vaccines will be a drag on 2026 growth, and investors should model Gardasil conservatively rather than betting on a China reopening.

Animal Health (the ballast)

Animal Health grew 6% ex-FX to $1.51B, with livestock up 9% across all species and companion animal flat as new-product growth was offset by fewer vet visits. It is a steady, counter-cyclical compounder that management expects to more than double by the mid-2030s.

Assessment: Underappreciated ballast. It will never move the needle in a single quarter, but a durable, high-quality, non-Keytruda-correlated business is exactly what the post-LOE story needs, and it deserves more credit in the sum-of-the-parts than the market typically gives it.

Key Topics & Management Commentary

Overall Management Tone: Confident and forward-leaning, with the emphasis deliberately shifted away from a soft-looking 2026 P&L and toward pipeline optionality and the long-term $70B opportunity. Management was most assured on Keytruda IP and Winrevair and most guarded on M&A speculation and on committing to interim-data disclosure timing. On the central question of whether Merck is structurally a low-grower, management pushed back firmly rather than defensively, framing 2026's LOE drag as non-strategic noise around a mid-single-digit underlying growth rate.

1. The Keytruda Patent Cliff and IP Runway

This is the whole investment case. Management laid out the patent estate in unusual detail: the compound patent expires December 2028, but a method-of-making patent runs to May 2029 and a method-of-use patent to November 2029, and Merck's confidence in defending those additional two has grown as case law has evolved. For planning it still assumes 2028.

"There is a potential that you are going to see protection actually make it through either May or November 2029. For planning purposes, we continue to assume 2028 because I think that is a conservative assumption... And I would also remind you that we do face the IRA as of the beginning of 2029." — Rob Davis, Chairman & CEO

Assessment: A potential 6–11 month extension is a meaningful call-option on billions of revenue, and the tone shift toward "we now think we can defend the full estate" is a genuine positive. But IRA price-setting bites at the start of 2029 regardless, so even the bull IP case does not eliminate the cliff; it softens the slope. Prudent to underwrite 2028.

2. Keytruda Qlex (Subcutaneous) Conversion

The subcutaneous formulation is Merck's primary tool to retain share through the IV LOE. Qlex did $35M in Q4 ($40M for the year), with a permanent US J-code expected in April to unlock reimbursement. Management reiterated a 30–40% conversion target by 2028 and has priced Qlex to drive the switch.

"We continue to think we are going to see 30% to 40% adopted as you get out to 2028, and we will drive that as high as we can. And... we have priced this to drive for the adoption from Keytruda IV to Qlex." — Rob Davis, Chairman & CEO

Assessment: The strategy is coherent and the J-code catalyst is near-term and concrete. But $35M in the launch quarter against an $8.4B franchise shows how much has to happen in a short window; the 30–40% target is the single most important assumption in the entire Merck model, and it is still almost entirely ahead of the company.

3. The $70B Mid-2030s Opportunity

Management raised its line-of-sight "non-risk-adjusted" commercial opportunity to over $70B by the mid-2030s, up $20B from a year ago and, as it repeatedly noted, more than double consensus 2028 peak Keytruda of ~$35B. It said ten programs could be substantially de-risked over the next two years and that substantially all of the $70B will be de-risked by 2027.

"We now have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than just a year ago and more than double consensus 2028 peak Keytruda revenue of $35 billion." — Rob Davis, Chairman & CEO

Assessment: The framing is deliberately bullish and the "non-risk-adjusted" qualifier matters: this is the gross prize, not a probability-weighted forecast. The important commitment is the 2027 de-risking timeline, which gives investors a concrete checkpoint. We treat the $70B as a menu of optionality to be discounted heavily until the Phase 3 readouts land, not as a base-case revenue number.

4. MK-1406 (ex-CD388) and the Cidara Acquisition

The 2026 EPS optics are dominated by the ~$9B (~$3.65/share) upfront R&D charge for Cidara Therapeutics, whose lead asset MK-1406 is a potentially first-in-class long-acting, strain-agnostic flu-prevention antiviral that management pegs at >$5B in revenue potential. The Phase 3 ANCHOR trial completed Northern Hemisphere enrollment, with Southern Hemisphere enrollment underway to broaden the dataset.

"We believe MK-1406 has greater than $5 billion in revenue potential and can be a meaningful driver of growth later this decade and through the next." — Rob Davis, Chairman & CEO

Assessment: A sensible, on-strategy bolt-on that fits Merck's ~$15B "sweet spot" and infectious-disease heritage, and the severe current flu season is a useful real-world tailwind for the ANCHOR event rate. The accounting charge is noise; the question is execution risk on a novel preventative category with no direct precedent. We would not pay for the >$5B today.

5. sac-TMT (TROP2 ADC) Strategy and Ambition

Questioned on whether its TROP2 ADC development was too conservative relative to AstraZeneca/Daiichi, management pushed back, framing sac-TMT as a "workhorse" ADC with best-in-class potential across 16 Phase 3 studies (11 of which it views as first-in-class).

"We think sac-TMT has the potential to be best in class trope two-directed ADCs... I would challenge a little bit the characterization that we do not have a robust and ambitious program. We have 16 phase three studies." — Dr. Dean Li, President, MRL

Assessment: sac-TMT is one of the larger swing factors inside the $70B, and the breadth of the program is real. The competitive intensity in TROP2 is also real, and Merck's more measured indication strategy could prove either disciplined or too slow. This is a "show me the data" asset, with the key readouts landing in 2027.

6. HIV: Islatravir Two-Drug Regimens

Merck reported positive Phase 3 results for its once-daily doravirine/islatravir two-drug regimen, non-inferior to Biktarvy, with a PDUFA of April 28. It also has a once-weekly oral islatravir/lenacapavir regimen with Gilead and a monthly oral PrEP candidate (MK-8527).

"There will be an excitement of having a two-drug combo without an Insti backbone. Equally important... we are driving a two-drug regimen for the first q-weekly offering." — Dr. Dean Li, President, MRL

Assessment: A credible re-entry into HIV that plays to a genuine unmet need (integrase-sparing regimens, weekly and eventually monthly dosing). Against Biktarvy's entrenched position, commercial uptake is the open question, but the near-term April PDUFA gives the thesis a concrete 2026 catalyst.

7. Enlicitide (Oral PCSK9) and the Cardiometabolic Push

Enlicitide, an oral PCSK9 inhibitor, posted statistically significant, sustained reductions in LDL-C, ApoB, non-HDL-C, and Lp(a) across the CORALreef Lipids and HeFH Phase 3 studies, with Add-on data due at ACC in March and the Outcomes trial fully enrolled. It earned an FDA National Priority Voucher.

"Cardiovascular disease is the leading cause of death globally, and we look forward to bringing a potential new option to help address the CV epidemic." — Rob Davis, Chairman & CEO

Assessment: An oral PCSK9 with antibody-like efficacy addresses a very large market currently gated by injectable burden, and the data so far support the profile. The commercial prize hinges on the outcomes trial and on payer positioning against cheap generic statins, but this is one of the more tangible near-term pillars of the $70B.

8. TL1A (Tulisokibart) and Immunology Optionality

On its TL1A inhibitor, management framed the class as a potential "third node" in inflammation alongside TNF and IL-23, with the near-term focus on the ATLAS ulcerative-colitis Phase 3 readout and studies underway across six diseases. It hinted at combination and bispecific strategies without committing publicly.

"Our ambition is to be the first and best in class TL1A. We are studying it in six diseases... I can assure you that that concept of we intend to be first and best, but also that we have a robust plan for being next is well in line." — Dr. Dean Li, President, MRL

Assessment: Immunology is a large, durable end market and a credible source of post-Keytruda diversification. The competitive field in TL1A is crowding quickly, so speed matters; the ATLAS UC readout this year is the gating event.

9. Capital Allocation and M&A Discipline

Pressed on large-deal rumors, management declined to comment but reiterated an unchanged framework: prioritize internal investment, a growing dividend, and disciplined BD, with a ~$15B "sweet spot" and willingness to go bigger for the right science. Guidance assumes ~$3B of buybacks and no additional significant BD.

"Obviously, looking in the area up to $15 billion as our sweet spot, but... for the right scientific deal, we would go bigger, but using the same methods, the same discipline." — Rob Davis, Chairman & CEO

Assessment: The BD track record (Verona, Cidara, plus the Hengrui license) is disciplined and on-strategy, but a stated openness to going "bigger" is a double-edged message with the stock at a 52-week high. A large, dilutive transformational deal is the swing risk to capital-allocation credibility investors should watch.

10. Margin Trajectory and the 2026 Cost Program

Q4 operating margin compressed to 20.9% as investment ran ahead of revenue, but 2026 guidance assumes gross margin recovers to ~82%, supported by the multi-year optimization initiative targeting $3B of cost savings by the end of 2027.

"Excluding these charges, operating expenses were flat, reflecting an increase in investment in support of our innovative pipeline and key growth drivers, offset by the benefits of our multiyear optimization initiative." — Caroline Litchfield, CFO

Assessment: The cost program provides a partial self-help offset to the LOE drag and lends credibility to the gross-margin recovery embedded in the guide. It is not, however, a growth strategy, and margin expansion from cuts has a finite runway.

11. WinRevair Durability and Label Expansion

Beyond the reported quarter, management leaned into Winrevair's longer-term optionality: the Phase 2 CADENCE study met its primary endpoint in combined pre- and post-capillary PH due to HFpEF, supporting a future Phase 3, and investigators are probing additional pulmonology and connective-tissue-disorder settings.

"The way that I would... think about Winrevair and what Winrevair may be doing to right heart failure and PAH is similar to what Merck showed for ACE inhibitors back in the day in relationship to left heart failure." — Dr. Dean Li, President, MRL

Assessment: The ACE-inhibitor analogy is ambitious, but the CADENCE proof-of-concept genuinely expands Winrevair's addressable population beyond PAH. Label expansion is the mechanism that could take Winrevair from a promising launch to a franchise large enough to matter against the cliff.

Guidance & Outlook

The reported EPS guide of $5.00–5.15 will screen as a large miss versus the Street's $5.36, but the entire gap and more is the one-time ~$9B ($3.65/share) upfront charge for Cidara plus $0.30/share of ongoing MK-1406 carrying cost. Add those back and the midpoint is roughly $9.03, essentially flat against 2025's $8.98. Revenue guidance of $66.25B at the midpoint versus $67.6B Street is the cleaner disappointment. It reflects roughly $2.5B of headwind from generic competition (the Januvia family, Bridion, Difficid), IRA price-setting, and the restructured Koselugo agreement, along with a still-declining Gardasil and softer Lagevrio, partly offset by new-launch momentum, oncology, and Animal Health, plus a ~1 point FX tailwind.

Implied ramp: After ~$2.5B of gross headwinds, hitting the +1% to +3% guide requires the growth portfolio (Keytruda, Winrevair, Capvaxive, Ohtuvayre, Welireg, Animal Health) to deliver mid-single-digit-plus growth to net back to roughly flat-to-up. Management's framing is that ex-LOE, the strategic base is growing ~5–8%.

Street at: Consensus sat at ~$67.6B revenue and ~$5.36 EPS pre-print. Expect revenue estimates to come down ~2% and reported EPS to reset for the charge; ex-charge EPS estimates should hold near $9.

Guidance style: Historically conservative. Merck met its 2025 sales guidance despite the Gardasil China shock and has beaten EPS in each of the last four quarters, so the initial 2026 guide likely embeds room. The revenue softness is real, but the "beat-and-raise through the year" pattern argues against taking the opening guide at face value.

Analyst Q&A Highlights

MK-1406 (CD388) and Interim-Data Timing

The opening question probed whether the severe Northern Hemisphere flu season could push the event-driven ANCHOR trial ahead of plan and whether an interim disclosure was coming. Management confirmed Northern Hemisphere enrollment is complete and Southern Hemisphere recruitment is underway, but declined to commit to interim-communication timing, emphasizing the need for robust data across subpopulations for the future label.

Q: "The flu season appears to be strong this season, so it would seem like the event rates may be occurring ahead of the plan in the ANCHOR trial... should we expect an interim disclosure in March or after March or not?"
— Mohit Bansal, Wells Fargo

A: "This is an event-driven trial. I want to have the right trial size... but most importantly, I need to make sure that I have strong data throughout a series of subpopulations that will be important for the future label. So at this time, we have not spoken about communication plans following IA."
— Dr. Dean Li, President, MRL

Assessment: Management is protecting the label breadth rather than chasing a headline interim, which is the right long-term call but removes a potential near-term catalyst. The refusal to commit to timing is the notable tell.

TROP2 ADC (sac-TMT) Development Ambition

A pointed challenge questioned whether Merck's TROP2 strategy was too conservative versus AstraZeneca and Daiichi, given the asset's differentiation. Management rejected the framing directly, citing the breadth of the program and its intent to be first in select tumor types.

Q: "I am kind of curious why your Trope-two development strategy seems to be relatively conservative versus what AstraZeneca and Daiichi are exploring, especially if you have a differentiated asset."
— Akash Tewari, Jefferies

A: "I would challenge a little bit the characterization that we do not have a robust and ambitious program. We have 16 phase three studies... we think sac-TMT has the potential to be best in class trope two-directed ADCs."
— Dr. Dean Li, President, MRL

Assessment: The defensiveness of the response is itself informative; the Street is skeptical Merck is moving fast enough in a fiercely competitive class. The 16-trial breadth is genuine, but breadth is not the same as speed to the largest indications.

Keytruda IP Runway and Qlex Ramp

A recurring line of questioning pressed on how to model the Keytruda US LOE given SEC-filing references to patents expiring in 2029, and on the Qlex ramp ahead of biosimilars. Management gave its fullest public articulation yet of the patent estate and reiterated conservative 2028 planning.

Q: "Consensus currently anticipates Keytruda's US LOE to occur in 2028. However, Merck's SEC filings suggest potential for two additional patents that expire in '29. So how should we model the IP runway for Keytruda?"
— Alexandria Hammond, Wolfe Research

A: "Our confidence that we will be able to defend those additional two patents has grown... For planning purposes, we continue to assume 2028 because I think that is a conservative assumption... whether it is '28 or '29 does not change the strategy we are following."
— Rob Davis, Chairman & CEO

Assessment: The most important exchange of the call. A credible path to 2029 is a real call-option, but management wisely refuses to let anyone model it, and IRA still hits in 2029. The strategy is cliff-agnostic, which is the right posture.

Big-Picture Growth Durability

The sharpest challenge questioned whether Merck is structurally a company that "grows modestly in good times and significantly pressured in less good times." Management pushed back at length, separating one-time LOE noise from what it framed as a mid-single-digit strategic growth base.

Q: "Is this what we should expect from Merck going forward? A company that grows modestly in good times and significantly pressured in less good times, or can Merck achieve sustainable, strong sales growth in the decade ahead?"
— Steve Scala, TD Cowen

A: "If you adjust for the LOE period we had... we actually are giving guidance of growth in... roughly 5% to 8% range over time, which actually is pretty strong growth... What is the sustainable strategic growth of those assets long term, not what are the one-time nonstrategic LOEs we are facing this year."
— Rob Davis, Chairman & CEO

Assessment: This is the bull-bear crux stated plainly. Management's ex-LOE 5–8% framing is plausible but self-serving; the market will not pay for it until the pipeline demonstrably fills the Keytruda hole. Until then, the reported low-single-digit growth is what sets the multiple.

HIV Two-Drug Regimen Positioning

Questioning sought to contextualize the importance of a dual regimen versus the Biktarvy triple-therapy standard of care. Management emphasized islatravir's differentiated mechanism, the appeal of an integrase-sparing option, and the strategic prize of weekly and eventually monthly dosing.

Q: "Can you just contextualize the importance of a dual regimen versus the standard of care of bictegravir Biktarvy, and what is the feedback in more broadly unmet need for a dual regimen versus the standard of care triple?"
— Evan Seigerman, BMO Capital Markets

A: "There will be an excitement of having a two-drug combo without an Insti backbone. Equally important... we are driving a two-drug regimen for the first q-weekly offering... there is no weekly three-drug or two-drug."
— Dr. Dean Li, President, MRL

Assessment: The weekly and monthly optionality is the real differentiator, not the daily two-drug itself. Displacing Biktarvy is hard, but the dosing-convenience angle gives Merck a defensible wedge into a large, sticky market.

Business Development Strategy Amid Deal Rumors

A question tried to reconcile the $70B organic opportunity with the track record of ~$10B-and-under deals against a large transaction reportedly in the press. Management declined to address the rumor and restated its disciplined framework.

Q: "I am trying to balance the fact that you are laying out a $70 billion non-risk adjusted revenue opportunity for the current pipeline... versus the large deal that has been in the press lately. I am just trying to balance it all."
— Umer Raffat, Evercore ISI

A: "Obviously, we do not comment or speculate on market rumors... Where we see those things align, we move, but we have always done it with discipline... looking in the area up to $15 billion as our sweet spot, but... for the right scientific deal, we would go bigger."
— Rob Davis, Chairman & CEO

Assessment: The non-denial of a large deal, paired with an explicit willingness to "go bigger," is a subtle signal that a transformational transaction is on the table. That is the biggest wildcard to capital-allocation discipline and the 2026 buyback assumption.

MK-3000 (Wnt Agonist) in Retinal Disease

A question sought the basis for management's confidence in MK-3000 and the size of the opportunity ahead of 2026 data. Management framed it as the first non-VEGF mechanism in a large DME/AMD market where 30–40% of patients respond poorly to anti-VEGF therapy.

Q: "It is obviously a new mechanism but also listed as one of your key near-term products for de-risking that $70 billion. Can you help set the stage in terms of what gives you such confidence in this asset and how large of an opportunity you see?"
— Christopher Schott, JPMorgan

A: "This is the first pathway that is based on the genetics of vascular stability in the eye... Historically, up to forty percent have individuals that have suboptimal response to VEGFs... that is about a $15 billion market... it is really the combination of both of those assets that... is a greater than $5 billion opportunity."
— Dr. Dean Li / Rob Davis

Assessment: A genuinely differentiated mechanism in a large market with a clear unmet-need wedge (VEGF non-responders). Management flagged it as underappreciated, and we agree it is one of the more overlooked pillars of the $70B, though it remains a data-dependent 2026 story.

What They're NOT Saying

1. No standalone long-term financial framework. Management quantifies a $70B "non-risk-adjusted" opportunity but declines to translate it into a risk-adjusted revenue or EPS trajectory through the LOE. The absence of a multi-year financial bridge across 2028 is the single biggest disclosure gap.
2. No specific Keytruda erosion curve. The 30–40% Qlex conversion target is offered without a corresponding assumption for how fast IV Keytruda revenue declines post-LOE. Investors are left to model the net hole themselves.
3. MK-1406 interim timing dodged. Despite a flu season that should be accelerating ANCHOR event rates, management would not commit to whether or when interim data would be disclosed, damping a potential 2026 catalyst.
4. Large-deal rumor neither confirmed nor denied. The refusal to address a reported large transaction, combined with "we would go bigger," leaves the buyback assumption and balance-sheet capacity as open questions.
5. Gardasil China has effectively no recovery path in the guide. Management confirmed no China shipments and did not lay out conditions for resumption, and the CDC single-dose HPV change was not quantified as a 2026 headwind.
6. Segment-level margins. The sharp operating-margin compression to 20.9% was attributed to "investment," but management gave no detail on where the incremental spend is concentrated or when the launch-investment intensity peaks.

Market Reaction

• Pre-print setup: MRK closed at $113.37 the day before the print, its 52-week closing high, up 7.7% YTD, 13.6% over the trailing 12 months, and 6.5% over the trailing 30 days. The stock had recovered more than 50% from its mid-2025 low of $73.47, so it entered the print with expectations rebuilt.
• Reaction (BMO, same-day session): Shares initially fell ~2% in the pre-market on the light-looking 2026 guide (touching ~$111), then reversed and closed +2.2% at $115.84, a fresh 52-week high, on ~25.8M shares (2.0x the 30-day average).

The intraday round-trip tells the story: the market's first instinct was to sell the headline revenue and EPS guide, but it quickly looked through the one-time Cidara charge to a clean Q4 beat and a dense run of pipeline catalysts (the Keytruda ovarian-cancer PDUFA, subcutaneous Keytruda progress, and positive Enflonsia RSV data all clustering within days). Closing at a 52-week high on 2x volume, against an S&P that fell 0.8% on the day, signals that patient holders are willing to underwrite the transition. It also means the stock is no longer discounting bad news, which raises the bar for the next few prints.

Street Perspective

Debate: Is the 2026 Guide a Real Disappointment or an Accounting Illusion?

Bull view: The entire EPS shortfall is the one-time Cidara charge; ex-charge EPS is flat at ~$9.03, revenue still grows against ~$2.5B of well-telegraphed LOE headwind, and Merck has a long history of guiding conservatively and beating.

Bear view: Strip the accounting noise and Merck is still guiding to roughly no growth in a year the market is up, with the biggest patent cliff in the industry two years out and a vaccine franchise in secular decline.

Our take: Both are right, which is why the stock round-tripped. The EPS "miss" is optics, but the revenue softness is genuine and the growth profile is uninspiring until the pipeline converts. Net neutral, which supports a Hold rather than a call in either direction.

Debate: Does the Pipeline Actually Fill the Keytruda Hole?

Bull view: A $70B mid-2030s opportunity, more than double peak Keytruda, with ten programs de-risking by 2027 (Winrevair expansion, enlicitide, sac-TMT, MK-1406, TL1A, MK-3000, HIV) is more than enough, and the IP could stretch to 2029.

Bear view: "Non-risk-adjusted" is doing heavy lifting; historically only a fraction of such portfolios convert, and no single asset rivals Keytruda's scale, so the base case is a multi-year earnings air-pocket around 2028–2029.

Our take: The breadth is real and unusually deep, but the market is right to demand proof before paying for it. The 2027 de-risking checkpoint is the key milestone; we would rather buy the confirmation than the promise.

Debate: Is ~12.8x Forward Cheap or a Value Trap?

Bull view: A best-in-class oncology and vaccines franchise, a growing dividend, and a deep pipeline at ~12.8x ex-charge forward earnings is a rare mispricing for a company management insists can grow mid-single-digits ex-LOE.

Bear view: Pharma facing a defining patent cliff routinely trades at low-teens multiples that compress further as the cliff approaches; the multiple is low for a reason and can stay low or de-rate into 2028.

Our take: Fair, not cheap, after a 50%+ recovery to a 52-week high. The valuation limits downside but the cliff caps upside, leaving a stock that should track the market. That balance is the essence of our Hold.

Model Update Needed

Valuation impact: At $115.84, MRK trades at ~12.8x 2026 ex-charge EPS (~$9.03) and ~12.9x 2025 non-GAAP EPS ($8.98), a below-market multiple appropriate for the LOE overhang. Our fair-value range of roughly $108–125 brackets the current price, implying limited near-term upside from spot and framing a total return (with the ~3.5% dividend yield) that should approximate the market. We would need either a de-rating catalyst removed (pipeline de-risking, Qlex traction) or a lower entry point to move to Outperform.

Thesis Scorecard Post-Earnings

Overall: Thesis established, balanced. The pipeline and launch pillars are confirmed and the valuation is reasonable, but the cliff, the vaccine drag, and a no-growth 2026 are equally confirmed. This is a quality franchise navigating a well-understood transition, with the reward and the risk roughly matched at the current price.

Action: Initiate at Hold. Own it for the dividend and pipeline optionality, but wait for pipeline de-risking or a lower entry to press the position. We would upgrade on evidence of Qlex conversion traction or a clean 2027 de-risking of the $70B; we would downgrade on a pipeline setback, a dilutive mega-deal, or accelerating Keytruda/Gardasil erosion.